Hill-Rom Holdings, Inc. (NYSE:HRC) CEO John J. Greisch sold 125,241 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the sale, the chief executive officer now directly owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Hill-Rom Holdings, Inc. (NYSE HRC) opened at $83.25 on Friday. The firm has a market capitalization of $5,386.79, a P/E ratio of 21.20, a price-to-earnings-growth ratio of 1.74 and a beta of 1.19. Hill-Rom Holdings, Inc. has a fifty-two week low of $54.80 and a fifty-two week high of $85.25. The company has a debt-to-equity ratio of 1.55, a current ratio of 1.77 and a quick ratio of 1.34.

Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.05. The firm had revenue of $738.30 million during the quarter, compared to analysts’ expectations of $731.10 million. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. Hill-Rom’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.18 EPS. equities analysts forecast that Hill-Rom Holdings, Inc. will post 4.26 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 15th will be issued a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, December 14th. Hill-Rom’s dividend payout ratio is presently 36.18%.

A number of research firms recently issued reports on HRC. Zacks Investment Research raised shares of Hill-Rom from a “sell” rating to a “hold” rating in a research report on Monday, September 18th. ValuEngine downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays increased their target price on shares of Hill-Rom from $86.00 to $90.00 and gave the stock an “overweight” rating in a research report on Monday, November 6th. Bank of America reissued a “hold” rating on shares of Hill-Rom in a research report on Wednesday, November 22nd. Finally, Stifel Nicolaus increased their target price on shares of Hill-Rom from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $89.57.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Hill-Rom by 3.1% in the 2nd quarter. BlackRock Inc. now owns 5,226,138 shares of the medical technology company’s stock worth $416,053,000 after acquiring an additional 159,074 shares during the period. State Street Corp boosted its holdings in Hill-Rom by 2.7% in the 2nd quarter. State Street Corp now owns 1,681,107 shares of the medical technology company’s stock worth $133,831,000 after acquiring an additional 43,645 shares during the period. Bank of New York Mellon Corp boosted its holdings in Hill-Rom by 4.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,288,471 shares of the medical technology company’s stock worth $95,348,000 after acquiring an additional 52,863 shares during the period. Wells Fargo & Company MN boosted its holdings in Hill-Rom by 298.1% in the 3rd quarter. Wells Fargo & Company MN now owns 1,133,900 shares of the medical technology company’s stock worth $83,908,000 after acquiring an additional 849,050 shares during the period. Finally, Koch Industries Inc. purchased a new position in Hill-Rom in the 2nd quarter worth approximately $1,007,000. Hedge funds and other institutional investors own 82.35% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “John J. Greisch Sells 125,241 Shares of Hill-Rom Holdings, Inc. (HRC) Stock” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/john-j-greisch-sells-125241-shares-of-hill-rom-holdings-inc-hrc-stock/1768965.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Insider Buying and Selling by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with Analyst Ratings Network's FREE daily email newsletter.